GST means Goods and Service Tax. It is an important step to control and reform the indirect taxes system in India.
India is one of the largest producer of pharma products and 3rd largest pharmaceutical industry in World. Health Ministry tries for the development of new technologies to end the year for treating diseases, such as tuberculosis and cancer.
Effect of GST on pharma Industry:
The Indian Govt. decided for the implementation of GST on Pharma industry, in which all the various taxes would merge into one uniform tax system.
Goods and Service Tax is expecting to have a positive impact on the Indian Pharmaceutical Industries as it will decrease the manufacturing cost, since eight different taxes are levied in the pharmaceutical industries helps in easy going business.The pharma sector is the one which is going to benefit a lot from this new move. The pharmaceutical industry deals with 8 different taxes and GST is going to demolish this problem of dealing with each one of them. It will streamline the taxes, making it just one tax to pay in the end for all the services being provided. Pharmaceutical companies are going to feel the difference as GST will rationalise their supply chain which adds up to 2% to the country’s pharmaceutical industry. The biggest benefit though GST will be a reduction in the overall transaction cost as CST (Central Service Tax) has been withdrawn.
Beside some positive impact, there are some negative impacts also. As GST is applicable on phases of the supply chain, it will have negative impact on Free-drugs samples, Bonus/Discount Schemes, Inter-state stock transfer, etc.
The move of launching GST is a good initiative taken by our government. Though the government looks forward to providing a good services to its people, it may take some time for the consumers and market to settle around it. GST seems to solve the problem of dealing with many taxes on various services. The changes are somewhat new for the consumers to understand but will surely benefit the wellness industry by all means.
HI CURE BIOTECH IS a main player in Pharma Industries Business in India.
Indian pharmaceutical area represents around 2.4 for every penny of the worldwide pharmaceutical industry in esteem terms and 10 for every penny in volume terms and is relied upon to extend at a Compound Annual Growth Rate (CAGR) of 15.92 for each penny to US$ 55 billion by 2020 from US$ 20 billion in 2015.
By 2016, India is required to be the third-biggest worldwide bland Active Pharmaceutical Ingredient (API) vendor showcase.
We have approximately 200+ products, which is probably the good range of product by a company in the country. We supply a wide range of pharmaceutical dosage like Tablets, Capsules, Syrups & Dry syrups, Injectables, Ophthalmic & ENT formulations, Herbal products, Dental products, Ointment & Creams etc in domestic and export market.
We have tie-ups with rumored GMP Certified/WHO consistent merchants, who help us take into account quality item necessities of our customers. Notwithstanding that we have the experience and information of Product Package planning and printing, which settles on Hicure Biotech a favored decision for Third-Party fabricating/Contract manufacturing for our customers.
Hi-Cure Biotech have devised a way to invent new medicines and get them to market cheaply to enable millions in poor countries to be cured of infectious diseases and potentially slashing the National Health Service drugs bill.
The process has the potential to undermine the monopoly of the big drug companies and bring cheaper drugs not only to poor countries.
Hi-Cure Biotech Ethical franchise program is developed to ensure maximum reach and availability of medicines. Ethical Pharma Franchise provide an opportunity to no. of youngster to start their own business by becoming a Ethical franchise partner on monopoly basis.
We started with this business module 7 years back and today we are working with more than 150 franchise partner across India for our products range from Antibiotic, Derma, Ayurvedic, Gynae etc..
Health Care Sector a gateway of new Business Opportunities
Healthcare sector in India is US $100 billion. We have a huge change in percentage of total spending on health by Indian people from 2010 to 2015, in 2010 it US$ 54 and in 2015 US$ 68.6. It shows now Indian people are aware for their health.
Awareness of people for their health, also growing the pharma industry in a domestic level. In the month of july 2015 growth of domestic Indian pharma was 12.6 %.
PCD Pharma Franchise
In Domestic retail market Indian pahrma industry cross huge growth sale in pharma medicines. Indian pharma domestic cross 90,000 crore sale.
Pharma industry of India is Third largest industry in the world. Indian government has liberal policies and regulation that has make pharmaceutical sector to overcome many challenges.
But there are still many challenges in pharma industry, Distribution & timely reach of medicines, to overcome from these challenges Indian Pharma Industry adopted a new technique i.e Pharma PCD Franchise.
Pcd Pharma Franchise a business module that adopted by Indian pharmaceutical industry, Pharma pcd stands for “Propaganda Cum Distribution- ship”.
In Pharma pcd business module pharmaceutical company not appointment MR & sales person, they are directly appointment pharma franchise operator. There is no middle men in pharma pcd business it reduces the healthcare medicine price and pharma company provides medicine as per competitive market.
In this business module pharma treading company offers monopoly rights with district and state wise.
Pharma pcd companies also provides Promotional & sale support like Visual ads. MR Bags, Executive Dairy, Pens, Brochure etc.
Pharma pcd business started from a very low investment & no target sale.
Pharma Monopoly Rights & PCD, Pharma Pcd Monopoly and Best Pharma PCD Products offer Wants Franchisee/PCD all over India for marketing & distribution with monopoly rights. pharma-monopoly-rights-in-Indore , Gujarat, Telangana.
Now a days people who are well experienced in Pharma Marketing wants to do their own business in pharma and predominately in marketing side, reasons are many , mainly dissatisfaction from the job.
Gujarat and Telangana have put sales of Swiss drugmaker Roche’s blockbuster drug Avastin on hold, officials said on Tuesday, after it hampered the vision of 15 patients who used it for a condition it is not officially meant to treat.
Avastin is a cancer drug but is often used by doctors to treat vision loss even though it has not been approved by the US Food and Drug Administration for that purpose. Studies have shown that eye injections of Avastin curb vision loss.
Roche’s India unit said the company does not promote the use of Avastin for treatments for which it is not approved, but has initiated an internal investigation.
HG Koshia, the top drug controller in Gujarat, said he had directed distributors to recall one batch of the medicine given to the patients last week. Its samples were being tested following the incident at a hospital in Ahmedabad city.
Following an alert from Gujarat, Telangana has ordered a freeze on all batches of Avastin being sold in the state, drug control official Surendranath Sai said.
“We are stopping other batches also till the dust settles,” Sai told Reuters. “We will release only if declared standard and safe for use.”
Many doctors around the world use Avastin “off label” to treat age-related macular degeneration, a leading cause of vision loss.
Such usage, Roche said in statement, “bears the risk of contamination and has already led to serious bacterial infections of the eye in other countries around the world”.
“Roche will cooperate fully with any investigations undertaken by the authorities … We are taking the events in Gujarat very seriously,” the statement said.
Fifteen patients at CH Nagri Municipal Eye Hospital in Ahmedabad underwent surgery last week after they reported swelling and pain in their eyes after being administered Avastin. Six patients are still in the hospital.
The hospital has administered the drug to 7,000 people over the last decade but has now stopped its usage, senior official Tejas Desai said.
Cases of shoddy medical treatment and spurious drugs are often reported in India, where the public health system remains overburdened and people, especially in smaller towns, struggle to access basic health services.
The hospital said all standard protocols were followed. Koshia, Gujarat’s drug regulator, said they would need to ascertain whether the drug was a fake copy of Avastin.
August 18, 2015: After tasting success in the realm of clinical trials, India, in recent times has created a big market for medical tourism. It is postulated that country’s medical tourism sector will soar to a $2 billion market by 2015, after a steep annual growth rate of 25%. The reasons for this industry to blossom are manifold. Availability of the most sophisticated medical equipment, easy access to the country by means of visa on arrival, and surgeries and medical procedures conducted at a fraction of costs as compared to the patient’s parent countries are some highlights which draw people to India. Currently, the United States, Europe and Africa are countries that look up to India for subsidized treatment, in which the quality of care is not compromised.
The Indian Railway Catering and Tourism Corporation (IRCTC) has devised an interesting concept, by which it will facilitate medical tourism for Indians in the country, especially from the north east frontiers of Kolkata, Guwahati, etc, who often travel to the South of India for medical procedures. In addition, the IRCTC will help transport patients and their relatives from Bangladesh to various centers in India, to avail treatment.
As an initial move, IRCTC will focus on the senior citizens and assist them in making travel reservations, catering to their medical and special needs during travel, obtain appointments with doctors, and help them with accommodation if required, before and after the procedure. This facility will not only be extended to the patients, but also to the accompanying relatives or friends, or to people who are not very savvy with coordinating and arranging travel.
Mr. Debashish Chandra, the GM of IRCTC East Zone commented that this is a service made available for the welfare of the needy and geriatrics, and is not intended to boost profits.